PLYX News

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care

Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events

Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders

Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial

Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™